GlassScriptPhysician profile
Juan E Lerma
NPI 1841279981
$351,481.75
in general payments reported to CMS, 2019-2025
23 companies · $115K in 2025
The $115K reported for 2025 was more than what 99% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,855 · 2020: $14K · 2021: $23K · 2022: $72K · 2023: $72K · 2024: $46K · 2025: $115K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $165K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $40K · Honoraria: $15K · Travel and Lodging: $5,057 · Grant: $4,407 · Food and Beverage: $3,152 · Education: $124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $165,276.76 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $39,662.31 |
| Honoraria | $14,750.00 |
| Travel and Lodging | $5,056.68 |
| Grant | $4,407.37 |
| Food and Beverage | $3,152.47 |
| Education | $124.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $52,635.25 | 2021-2025 | Filspari |
| Glaxosmithkline, LLC. | $45,162.37 | 2022-2025 | Jesduvroq, Benlysta, Arexvy |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $42,189.94 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $39,004.62 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $27,516.77 | 2019-2025 | Lokelma, Farxiga |
| Otsuka America Pharmaceutical, INC. | $26,924.17 | 2020-2025 | Jynarque |
| Novo Nordisk INC | $19,873.76 | 2024-2025 | Ozempic |
| Calliditas Therapeutics US INC. | $19,198.30 | 2022-2024 | Tarpeyo |
| Novartis Pharmaceuticals Corporation | $18,579.55 | 2022-2024 | |
| Vertex Pharmaceuticals Incorporated | $15,274.12 | 2023-2025 | |
| Vifor Pharma, INC. | $10,800.45 | 2021-2025 | Veltassa |
| Opko Pharmaceuticals, LLC | $9,015.76 | 2024-2025 | Rayaldee |
| Boehringer Ingelheim International Gmbh | $7,756.87 | 2022-2023 | Jardiance |
| Idorsia Pharmaceuticals US INC | $4,865.00 | 2025 | Tryvio |
| Akebia Therapeutics INC | $4,777.83 | 2020-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $4,750.00 | 2023-2024 | |
| Amgen INC. | $1,579.85 | 2019-2024 | Tavneos |
| Astrazeneca Uk Limited | $1,167.00 | 2022 | |
| Mallinckrodt Hospital Products INC. | $141.16 | 2024 | Terlivaz |
| Ardelyx, INC. | $92.23 | 2024-2025 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.22 | 2023-2025 | Jardiance |
| Fresenius USA Marketing, INC. | $60.35 | 2023 | Velphoro |
| Lilly USA, LLC | $29.18 | 2025 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Juan Lerma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.